BL-B01D1 — clinical trials using this drug

Public-registry trials using BL-B01D1 that Eichor's radar has found — 3 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.

Trial	Sponsor	Condition	Phase	Sites
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)	Sichuan Baili Pharmaceutical Co., Ltd.	Non-squamous Non-small Cell Lung Cancer	PHASE2 / PHASE3	2
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)	Sichuan Baili Pharmaceutical Co., Ltd.	Squamous Non-small-cell Lung Cancer	PHASE2 / PHASE3	2
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)	Sichuan Baili Pharmaceutical Co., Ltd.	Triple-Negative Breast Cancer (TNBC)	PHASE3	1

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →